Xemilofiban
| Code | Size | Price |
|---|
| TAR-T35161-5mg | 5mg | £1,155.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Xemilofiban is a biochemical.
CAS:
149820-74-6
Formula:
C18H22N4O4
Molecular Weight:
358.398
Purity:
0.98
SMILES:
CCOC(=O)C[C@H](NC(=O)CCC(=O)Nc1ccc(cc1)C(N)=N)C#C
References
Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). Am J Cardiol. 2008 Nov 1;102(9):1151-5. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. PubMed PMID: 18940282.
Gowda RM, Khan IA, Vasavada BC, Sacchi TJ. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism. Am J Ther. 2004 Jul-Aug;11(4):302-7. Review. PubMed PMID: 15266223.
Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. PubMed PMID: 19327416.
Sheppard LP. Xemilofiban Searle and Co. IDrugs. 1998 Jun;1(2):257-63. PubMed PMID: 18465540.